In vivo ADME study
Release time:
2023-09-22 11:08
Source:
In 2022, China's in vivo ADME market capacity is 100 million yuan (RMB), and the global in vivo ADME market capacity is 100 million yuan. It is expected that the global in vivo ADME market capacity will grow at a compound annual growth rate of% during the forecast period and reach 100 million yuan in 2028.
By product category, the in vivo ADME industry can be subdivided into small molecule drugs, biopharmaceuticals/macromolecular drugs. It is the largest revenue category in the ADME industry in the body. In 2022, the market size will reach 100 million yuan and the market share will reach%. It is expected that by 2028, it will still maintain its leading position and will reach% of the market share.
Classified by end-use applications, in vivo ADME can be applied to other fields, government and university institutions, biopharmaceutical companies, etc. At present, the demand in the field is the highest, accounting for the largest market share of the ADME industry in 2022. In addition, it is expected that the field will also have great demand potential during the forecast period, and the market size is expected to reach 100 million yuan in 2028.
The major enterprises in China's in vivo ADME industry are IQVIA, Evotec, Shanghai Ruizhi, Lonza, Aragen Life Sciences, Sai Life Sciences, Shanghai Medisi, Bioduro-Sundia, Eurofins Scientific, Kanglong Huacheng, Envigo, Charles River, RTI International, Tecan Group, Curia. The top three manufacturers (CR3) will account for about% of the market share in 2022. Among them, it is a leading domestic enterprise, with ADME sales and sales revenue of RMB 100 million in 2022.
Next Page
Next Page